Intraarticular Injection of Infliximab-Loaded Thermosensitive Hydrogel Alleviates Pain and Protects Cartilage in Rheumatoid Arthritis [Retraction].

Save

Chen W, Li Z, Wang Z, Gao H, Ding J, He Z. J Pain Res. 2020;13:3315–3329. https://doi.org/10.2147/JPR.S283518

We, the Editors and Publisher of the journal Journal of Pain Research, have retracted the published article.

After publication, concerns have been raised by a third party in 2025 about the integrity of the data in Figure 3B of the article.

Further investigation conducted by the Journal and Publisher confirmed unusual similarities present in the image panels representative of different treatment conditions in Figure 3B.

When approached for an explanation, the authors confirmed there are fundamental errors present in the article. Therefore, they have agreed to the retraction of this article. The authors apologise for this oversight.

We have been informed in our decision-making by our editorial policies and the COPE guidelines.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as ‘Retracted’.

Related articles

PubMed

Upadacitinib as a rescue therapy for steroid- and infliximab-refractory acute severe ulcerative colitis: short- and long-term effectiveness and safety in a multicenter cohort study.

Abstract Background Acute severe active ulcerative colitis (ASUC) often requires rescue therapy when standard medical treatment fails. Data on the use of upadacitinib (UPA) as a rescue option after failure of steroids and infliximab (IFX) and on the long-term outcomes of UPA treatment up to 48 weeks, remain scarce. Methods We evaluated hospitalized patients with ASUC (Truelove and Witts criteria) who received UPA following the failure of intravenous corticosteroids (IV-CS) and IFX. Outcomes...

PubMed

Refractory Idiopathic Infantile Pyoderma Gangrenosum Successfully Treated With Infliximab: A Case Report.

Pyoderma gangrenosum (PG) is a noninfectious neutrophilic dermatosis that can occur either idiopathically or secondary to various systemic conditions. PG is rare in childhood and even rarer in infancy. Due to its rarity, the pathophysiological mechanisms remain unclear. Although systemic glucocorticoids are considered the first‐line therapy, no standardized second‐line or subsequent therapeutic approach has been established, particularly for refractory cases. In this report, we present a case of...